IPP Bureau
Bristol Myers Squibb reports positive phase 4 data on Cobenfy for schizophrenia patients
By IPP Bureau - March 31, 2026
The open-label trial involved 105 adults with schizophrenia who were on a stable dose of an oral atypical antipsychotic for at least six weeks
Kenvue unleashes science-driven skincare offensive at American Academy of Dermatology meet
By IPP Bureau - March 31, 2026
The showcase, running March 27–31, puts a spotlight on everything from fine lines to daily sun protection
Samsung Biologics scores Blbig at 2026 CDMO Leadership Awards
By IPP Bureau - March 31, 2026
The CDMO Leadership Awards spotlight top-performing development and manufacturing service providers
Biocytogen partner NEOK Bio gets FDA nod for novel cancer therapy
By IPP Bureau - March 31, 2026
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
Bavarian Nordic seeks EMA nod for Mpox vaccine in children aged 2–11
By IPP Bureau - March 31, 2026
The trial demonstrated that immune responses in children were non-inferior to adults, with a similar safety profile after two standard doses of MVA-BN
Agilent bags FDA nod for key cancer diagnostic
By IPP Bureau - March 31, 2026
The FDA approval makes PD-L1 IHC 22C3 pharmDx the only companion diagnostic approved to detect tumors expressing PD-L1 in esophageal or GEJ carcinoma patients for KEYTRUDA treatmen
GSK seeks European nod for promising Hepatitis B therapy
By IPP Bureau - March 31, 2026
ENHERTU approved in China as first HER2-targeted ADC for early breast cancer
By IPP Bureau - March 31, 2026
The decision is based on the phase 3 DESTINY-Breast11 trial
Roche launches groundbreaking multiplex test to boost blood safety
By IPP Bureau - March 31, 2026
The new assay consolidates screening for four major viral threats into a single workflow
Teva hits major biosimilar milestones with FDA nod and regulatory filings
By IPP Bureau - March 31, 2026
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
Allergan Aesthetics showcases breakthroughs at AAD 2026
By IPP Bureau - March 31, 2026
Allergan also presented new insights on the growing population of patients on GLP-1 agonists for weight loss who are seeking aesthetic treatments
Bristol Myers Squibb’s Camzyos shows breakthrough results in adolescents with obstructive hypertrophic cardiomyopathy
By IPP Bureau - March 31, 2026
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
Lupin receives FDA’s tentative approval for Sugammadex injection
By IPP Bureau - March 31, 2026
Sugammadex injection is bioequivalent to Merck’s Bridion injection for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery
Corona Remedies acquires antiseptic brand Wokadine from Dr Reddy’s to enter Iodine market
By IPP Bureau - March 31, 2026
This strategic acquisition enables CORONA Remedies to penetrate deeper into targeted specialty and offer wider accessibility
